型号:
产品价格:电议      采购度:1600      原产地:美洲
发布时间:2021/6/22 17:26:11 所属地区:国外 国外
简要描述:
Filgotinib (GLPG0634) 是一种选择性的 JAK 抑制剂,能够有效抑制 JAK1,JAK2,JAK3 和 TYK2 的活性,IC50 值分别为 10 nM,28 nM,810 nM 和 116 nM。
标签:GLPG0634
产品详情
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1206161-97-8
MCE 站:Filgotinib
产品活性:Filgotinib (GLPG0634) 是一种选择性的 JAK 抑制剂,能够有效抑制 JAK1,JAK2,JAK3 和 TYK2 的活性,IC50 值分别为 10 nM,28 nM,810 nM 和 116 nM。
研究领域:Epigenetics | Stem Cell/Wnt | JAK/STAT Signaling
作用靶点:JAK
In Vitro: Filgotinib (GLPG0634) dose-dependently inhibits the differentiation of Th2 cells mediated by IL-4, a cytokine that signals through JAK1 and JAK3. Filgotinib also inhibits Th1 differentiation with similar potencies of 1 μM or lower. Filgotinib (GLPG0634) does not inhibit JAK2 homodimer-mediated signaling induced by EPO or PRL (IC50 > 10 μM).
In Vivo: Filgotinib (GLPG0634; 3, 10, 30 mg/kg, p.o.) dose-dependently prevents disease progression in the therapeutic rat CIA model. Filgotinib (50 mg/kg, o.p.) protects bone and cartilage from degradation, effectively reduces infiltration of T cells (CD3+ cells) and macrophages (F4/80+ cells) in the paw, and decreases the serum levels of all cytokines and chemokines measured, including IL-6, IP-10, XCL1, and MCP-1. Filgotinib (GLPG0634; 0.1 and 0.3 mg/kg) shows efficacy in the rat CIA model.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | Epigenetics Compound Library | Immunology/Inflammation Compound Library | JAK/STAT Compound Library | Kinase Inhibitor Library | Stem Cell Signaling Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-COVID-19 Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | AG490 | Upadacitinib | AT9283 | Gandotinib | Lestaurtinib | Oclacitinib maleate | JANEX-1 | Cucurbitacin I | XL019 | Atractylenolide I | FLLL32 | Brevilin A | LFM-A13 | Ginsenoside Rk1 | ZM39923 hydrochloride | WHI-P154 | Curculigoside | FM-381 | RO8191 | Reticuline | Ilginatinib maleate | TCS 21311 | WHI-P97 | Protosappanin A | Coumermycin A1 | Dehydrocrenatidine | Delphinidin chloride | FM-479 | NSC 33994
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
更新时间:2024/1/2 10:12:11
留言咨询
温馨提示
1.遵守中华人民共和国有关法律、法规,尊重网上道德,承担一切因您的行为而直接或间接引起的法律责任。
2.请您真实的反映产品的情况,不要捏造、诬蔑、造谣。如对产品有任何疑问,也可以留言咨询。
3.未经本站同意,任何人不得利用本留言簿发布个人或团体的具有广告性质的信息或类似言论。
相关新闻
相关产品